Postanoxic Action Myoclonus (Lance-Adams Syndrome) Responding to Valproate
- 1 January 1979
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 36 (1) , 44-45
- https://doi.org/10.1001/archneur.1979.00500370074019
Abstract
• A patient with postanoxic action myoclonus (Lance-Adams syndrome) was severely disabled with this movement disorder. Valproate sodium was administered orally, with complete resolution of the myoclonus. This favorable response has been maintained for two years. Excessive yawning, the only side effect encountered, was dose related and was abolished with the addition of pimozide to the drug regimen.This publication has 4 references indexed in Scilit:
- Therapy of intention myoclonus with L‐5‐hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486Neurology, 1975
- DRAMATIC EFFECT OF METHYSERGIDE ON MYOCLONUSThe Lancet, 1974
- HVA and 5HIAA CSF measurements and 5HTP trials in some patients with involuntary movementsJournal of the Neurological Sciences, 1973
- EFFECTS OF DI‐n‐PROPYLACETATE, AN ANTICONVULSIVE COMPOUND, ON GABA METABOLISM1Journal of Neurochemistry, 1969